特一药业(002728.SZ):中成药产品储备较多,部分中成药产品的市场容量较大
格隆汇1月19日丨特一药业(002728.SZ)于2024年1月18日接受特定对象调研,就“公司未来是否重点发展中成药?中成药营收占比?”,公司回复称,公司中成药产品储备较多,部分中成药产品的市场容量较大,在国家产业政策大力支持中医药行业发展的背景下,公司将紧跟国家改革与发展的大趋势,重点发展中成药品种。
截至2022年,公司中成药类、化学制剂药类收入占比均在45%左右,化学原料药及化工产品收入占比在10%左右。2023年,由于中成药产品特别是核心产品特一止咳宝片保持了较好的增长,中成药产品的销售占比将进一步得到提高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.